A Phase Ib, Open Label, Single Arm, Multi-center, Dose Escalation Trial of Intravenous BI 836826 in Combination With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia
Latest Information Update: 15 Apr 2021
At a glance
- Drugs BI 836826 (Primary) ; Ibrutinib
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
Most Recent Events
- 08 Mar 2021 Status changed from to discontinued, as per Results published in the Investigational New Drugs
- 08 Mar 2021 Results published in the Investigational New Drugs
- 12 Jul 2019 Status changed from active, no longer recruiting to completed.